Jakarta, IDN Times – PT Merck Tbk has announced the approval of a final dividend payment for the 2025 financial year, totaling Rp123.2 billion or Rp275 per share. This significant decision was ratified during the company’s Annual General Meeting of Shareholders (AGMS), reflecting a robust financial standing and commitment to its shareholders.
The pharmaceutical giant experienced exceptional performance throughout 2025, demonstrating impressive growth across key metrics. Merck’s revenue surged by 16 percent, reaching Rp1.2 trillion, a notable increase from Rp1.04 trillion in 2024. This substantial top-line expansion laid the groundwork for remarkable improvements in profitability.
“This increase in revenue significantly propelled the company’s operating profit, which climbed by 66 percent, from Rp193 billion to Rp320 billion. Concurrently, our net profit for the year saw a substantial rise of 59 percent, reaching Rp244 billion, compared to Rp153 billion in the previous year,” stated Evie Yulin, President Director of PT Merck Tbk, in a press release issued on Wednesday (27/5/2026). Her remarks underscore a period of strategic success and operational efficiency.
Yulin further elaborated that Merck’s strong performance in 2025 and the first quarter of 2026 serves as a testament to its unwavering commitment to healthy and sustainable growth. This growth has been meticulously driven by the strengthening of its Healthcare business, diligent operational discipline, and a sharp focus on delivering broader benefits to society. The company’s total assets in 2025 soared to Rp1.27 trillion, marking an impressive 33 percent increase year-over-year. Furthermore, equity expanded by 21 percent, reaching Rp976 billion, primarily fueled by a significant rise in retained earnings. These financial indicators highlight Merck’s expanding business reach in the healthcare sector.
“Amidst the constantly evolving industry landscape, we remain dedicated to building an adaptive, resilient, and sustainably growing business. The company is deeply committed to continuously making a positive impact on both society and the broader healthcare ecosystem in Indonesia,” she affirmed. This forward-looking approach is complemented by the company’s robust financial management, as evidenced by a significant increase in operating cash flow throughout 2025, supported by enhanced cash receipts from customers and disciplined operational execution.
Carrying its positive momentum forward, Merck continued its impressive trajectory into the first quarter of 2026, recording approximately 32 percent growth compared to the same period in the previous year. This substantial growth was primarily fueled by increased sales across all business divisions, particularly its Healthcare products, catering to both key partners and export markets. Notably, in Q1 2026, diabetes products emerged as a leading contributor to the Healthcare business sales, accounting for 24 percent of the total and experiencing an outstanding 51.1 percent growth year-over-year. Beyond diabetes, other key products also showed strong performance, with fertility products growing by 18.2 percent, thyroid by 44.9 percent, and endocrinology by 2.4 percent. This surge in sales volume, coupled with a favorable product mix, propelled a 30 percent increase in gross profit compared to the corresponding period last year.
The exceptional financial performance in Q1 2026 further showcased a remarkable 380 percent surge in operating profit year-on-year, attributed to stringent operational cost efficiencies. Concurrently, the company’s cash and cash equivalents significantly improved, reaching approximately Rp443 billion by the end of March 2026, underpinned by enhanced operating cash flow. Merck is not only focused on financial gains but also on its commitment to responsible business practices and positive societal impact. The company firmly believes that scientific advancement and sustainable business practices must progress hand-in-hand to broaden access to healthcare for more patients.
Demonstrating this commitment, Merck’s environmental sustainability initiatives in 2025 successfully reduced Scope 1 and 2 greenhouse gas (GHG) emissions by an impressive 87.5 percent compared to its 2020 baseline, significantly exceeding its own 2030 target. This remarkable reduction was largely supported by the operation of rooftop solar panels since 2024 and the exclusive use of renewable energy for its operational facilities in Jakarta. Beyond emissions, the company continues to champion various other sustainability efforts, including optimizing water usage efficiency, implementing 4R-based (Reduce, Reuse, Recycle, Recover) waste management principles, and launching a reforestation program involving the planting of 1,000 mangrove trees to further support carbon emission reduction and ecosystem preservation.
Summary
PT Merck Tbk has approved a final dividend payment of Rp275 per share, totaling Rp123.2 billion, for its 2025 financial year. The company achieved strong financial performance, with revenue growing 16% to Rp1.2 trillion. Operating profit surged 66% to Rp320 billion, and net profit rose 59% to Rp244 billion.
This robust growth, driven by a strengthened Healthcare business, continued into Q1 2026 with approximately 32% year-on-year growth. Operating profit for Q1 2026 saw a remarkable 380% increase due to operational efficiencies. Furthermore, Merck significantly reduced Scope 1 and 2 greenhouse gas emissions by 87.5% in 2025, exceeding its 2030 target.